Published in final edited form as:

Gene. 2016 October 10; 591(1): 1–5. doi:10.1016/j.gene.2016.06.049.

Intraarticular Slow-release Triamcinolone Acetate Reduces Allodynia in an Experimental Mouse Knee Osteoarthritis Model

Jeffrey S. Kroin^{1,*,#}, Ranjan Kc^{2,#}, Xin Li², John L. Hamilton², Vaskar Das², Andre J van Wijnen³, Ole M. Dall⁴, Daniel A. Shelly⁵, Todd Kenworth⁴, and Hee-Jeong Im^{2,6,7,8,9}

¹Department of Anesthesiology, Rush University Medical Center, Chicago, IL

²Department of Biochemistry, Rush University Medical Center, Chicago, IL

³Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN

⁴TAK Biopharma, Copenhagen, Denmark

⁵Albumedix (Novozymes), Cincinnati, OH

⁶Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL

⁷Department of Internal Medicine (Section of Rheumatology), Rush University Medical Center, Chicago, IL

⁸Department of Bioengineering, University of Illinois at Chicago, Chicago, IL

⁹Jesse Brown Veterans Affairs Medical Center, Chicago, IL

Abstract

Intraarticular steroid injection has been the mainstay of short-term treatment of knee osteoarthritis (OA) pain. However, the duration of therapeutic effect from a single injection is not as long as desired. In this study we use a viscous formulation of triamcinolone acetate (TCA) in hyaluronic acid to prolong the anti-allodynia effect of that steroid. OA was induced in mice by a partial medial meniscectomy. Over time the animals developed a mechanical allodynia in the injected leg. Mice were then given a single intraarticular injection of TCA in a short-acting DMSO formulation, or a standard commercial suspension, or the drug formulated in 5% hyaluronic acid for slow-release. Control injections in OA mice were PBS or 5% hyaluronic acid vehicle. Mechanical allodynia was then monitored over the therapeutic period. Organotypic spinal cord slices and DRG culture were performed to assess whether TCA attenuates expressions of pain mediators induced by interleukin 1 β . TCA 40 μ g in a fast-releasing DMSO formulation produced relief from mechanical allodynia for a few days compared to PBS control injections ($P=0.007$).

*Correspondence to: Dr. Jeffrey S Kroin, Department of Anesthesiology, Rush University Medical Center, 600 S. Paulina, St., Chicago, Illinois, 60612. Telephone: 312-942-6460. FAX: 312-942-5773. Jeffrey_kroin@rush.edu.

#Jeffrey Kroin and Ranjan Kc contributed equally to these studies.

COMPETING INTERESTS

The authors declare that there are no competing interests involved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Similarly, the commercial suspension of TCA 40 µg also produced relief from mechanical allodynia for a few days compared to PBS control injections ($P=0.001$). However, TCA 100 µg in 5% hyaluronic acid produced relief from mechanical allodynia for at least 28 days compared to PBS control or 5% hyaluronic acid vehicle injections ($P=0.0005$). Furthermore, TCA significantly suppressed expression of pain mediators induced by interleukin 1 β in spinal cord and DRG organotypic culture. Intraarticular TCA in a sustained release formulation of viscous 5% hyaluronic acid will produce a long-term attenuation of mechanical allodynia in the OA knees of mice.

Keywords

Pain; Triamcinolone acetate; Allodynia; Hyaluronic acid

INTRODUCTION

Joint degeneration caused by osteoarthritis (OA) leads to chronic knee joint pain that affects >100 million individuals all over the world. Pain accounts for most primary care visits for OA, and is one of the key reasons why people with OA choose to have knee replacement surgery (TKR).¹ In the United States alone, there are almost one million TKR each year to treat OA and OA pain, with the projected number of TKR for 2030 expected to reach 3.5 million.² Prior to TKR, knee pain patients will have used noninvasive non-surgical alternatives such as systemic NSAIDs and analgesics for years. For more severe pain, intraarticular (IA) steroid injections have been the mainstay of short-term treatment of knee OA pain.^{3–6} However, the duration of therapeutic effect from a single injection is not as long as needed for a chronic pain condition,^{3,6} and so patients may drop the therapy due to injection frequency. To extend the period of pain relief, there are ongoing clinical trials on the efficacy of new IA triamcinolone acetate (TCA) formulations.^{7,8}

Physiological mechanisms of pain operate at the local joint level, the dorsal root ganglion (DRG) level, spinal level and higher brain processing centers. Several nociceptive molecules are recruited into the OA joint, including nerve growth factor (NGF), calcitonin gene-related peptide (CGRP), tumor necrosis factor- α (TNF α) and chemokine (C-C motif) ligand 2 (CCL2) and can cause activation of peripheral nociceptors.^{9–11} During chronic OA, the nociceptive system can become sensitized, leading to a heightened sensitivity. Steroids are proven, both scientifically and clinically, to be effective at reducing pain in knee OA. It has been suggested that TCA exert a potent anti-inflammatory effect on joints by inhibiting inflammatory cytokines and thus reduces pain.¹² However, the mechanism by which TCA alleviates knee OA pain is still not clearly defined.

In this study we use a viscous formulation of triamcinolone acetate (TCA) in hyaluronic acid (HA) to prolong the anti-allodynic effect of that steroid. While the use of HA alone as an IA-injected viscosupplement to reduce knee pain is a controversial issue,¹³ we are using HA to entrap the TCA molecule and thus slow its release. Furthermore, to delineate analgesic mechanism of TCA, we also performed organotypic culture of spinal cord slices and DRG.

METHODS

OA Model

The study was approved by the IACUC of Rush University Medical Center. OA was induced by partial medial meniscectomy in C57/BL6 mice (20 g).¹⁴ Briefly, mice were anesthetized with 1.5% isoflurane (Abbott Laboratories) in oxygen and the left knee was shaved and prepared for aseptic surgery. A medial para-patellar arthrotomy exposed the anterior medial meniscotibial ligament, which was elevated with a microprobe and severed using curved dissecting forceps. The medial meniscus was freed from its attachments to the margin of the tibial plateau and approximately one third of the medial meniscus was removed (approximately 1 mm of tissue). The patella was repositioned, and the skin incision closed with 5–0 polypropylene sutures. This surgically-induced OA model is slightly modified from OA model of destabilization of the medial meniscus, referred to as DMM. In prior studies this medial meniscus transection model has been shown to produce cartilage degeneration and mechanical allodynia by 4 weeks post-surgery.¹⁴

Evaluation of Mechanical Allodynia

Force withdrawal thresholds, in response to mechanical stimuli, were assessed using von Frey filaments applied to the plantar hindpaw, using an iterative up-down method.¹⁵ Animals were tested prior to and at 3 day intervals after OA induction surgery to determine when mechanical allodynia had developed (force withdrawal threshold < 2 g).⁹

Drug Treatment

Once mechanical allodynia developed (at least 6 weeks after surgery), mice were briefly anesthetized with 1.5% isoflurane and given a single percutaneous intraarticular injection, through a 30-gauge needle, of drug or control solution. Withdrawal thresholds were assessed using von Frey filaments until the therapeutic effect had worn off in the drug group (threshold back below 2 g).

Experiment 1 (fast-release; 2 groups): Active drug was TCA powder (Ark Pharm Inc., Libertyville, IL), dissolved in DMSO at 8 mg/mL so a 5 μ L injection was 40 μ g total dose. Control injection was PBS.

Experiment 2 (slower-release; 2 groups): Active drug was a commercial TCA suspension (Kenalog-10; Bristol-Myers Squibb) at 10 mg/mL so a 4 μ L injection was 40 μ g total dose. Control injection was PBS.

Experiment 3 (sustained-release; 3 groups): Active drug was 50 mg TCA powder hand-mixed into 2.5 mL (2.5 g) of 5% HA solution producing a clear 20 mg/mL TCA mixture; so a 5 μ L injection was 100 μ g total dose. To produce the 5% HA vehicle, HA powder (sodium hyaluronate; 1000 kDa; Novozymes, Cincinnati, OH) was dissolved in PBS to produce a very viscous (200,000cP), but easy to inject clear solution. The 5% HA solution was autoclaved for sterility. One control injection was PBS, and the other 5% HA alone.

The 40 μ g TCA dose for Kenalog-10 was based on the manufacturer's recommendation of 2.5 mg to 5 mg (assume 4 mg average) for the initial dose for an IA injection. Assuming a

normal mouse knee joint synovial volume of 4–5 μ L (based on our preliminary dye-injection experiments) and a normal human knee joint synovial volume of 0.5 mL,¹⁶ 100 $\times$ larger, the equivalent mouse dose was estimated as 4 mg/100 = 40 μ g (Experiment 2). We used the same 40 μ g dose for the TCA-DMSO injections (Experiment 1). For the TCA-HA injections (Experiment 3) we choose a larger dose, 100 μ g, since with the expected release to be spread out over weeks we wanted our daily dose to be above a threshold, so we would have an effect within the first few days after injection (as with TCA-DMSO or TCA-Kenalog).

Organ culture experiments

Organotypic slice cultures of spinal cord and dorsal root ganglia (DRG) were prepared from adult mice (20g) as previously described.^{17,18} After decapitation, the spinal cord and bilateral lumbar DRGs from L1 to L6 were aseptically removed and placed into ice-cold Hanks Balanced Salt Solution (HBSS) (Life Technologies, Carlsbad, CA). Lumbar spinal cords were transversely sliced into 1 mm thickness for spinal cord organ culture. The ganglia and spinal cord slices were transferred in serum free DMEM/F12 (Life Technologies, Carlsbad, CA) containing interleukin 1 β (IL-1 β) (10ng/mL) (PeproTech, Rocky Hill, NJ), TCA in DMSO (1mg/mL) or combination of IL-1 β and TCA and incubated for 24 h at 37°C in a humidified 95% air/5% CO₂ incubator. At the end of the culture period the ganglia and spinal cord slices were harvested, quickly frozen on dry ice, and stored at –80°C until they were assayed.

Reverse Transcription and Quantitative Polymerase Chain Reaction

Total RNA was isolated using the Trizol reagent (Life Technologies, Carlsbad, CA) following the instructions provided by the manufacturer. Reverse transcription (RT) was carried out with 1 μ g total RNA using the qScript™ cDNA SuperMix (Quanta Biosciences Inc, Gaithersburg, MD) for first strand cDNA synthesis. For quantitative PCR (qPCR), cDNA was amplified using the MyiQ Real-Time PCR Detection System (Bio-Rad Hercules, CA). Relative mRNA expression was determined using the C_T method, as detailed by the manufacturer (Bio-Rad Hercules, CA). GAPDH was used as an internal control. The values represent the mean of three separate experiments. The primer sequences will be provided upon request.

Statistics

Withdrawal thresholds (g) over time were compared between groups with repeated measures general linear model (SPSS software). Group comparisons at individual time points were by t-test or ANOVA, with step-down Bonferroni correction for multiple comparisons. For qPCR results, statistical significance was determined by Student's t-test. *P* values lower than 0.05 were considered to be statistically significant.

RESULTS

TCA-DMSO experiment

The von Frey force withdrawal thresholds are presented in Fig. 1. Before DMM surgery, thresholds were 5–6 g. After surgery, thresholds gradually decreased to < 2 g (allodynia). Mice receiving an intraarticular injection of TCA in DMSO vehicle had higher withdrawal

thresholds than PBS-injected mice over the day 1–7 post-injection period ($F=10.3$, $P=0.007$). On days, 1 and 3, these differences were also significant.

Commercial TCA suspension experiment

The von Frey force withdrawal thresholds are presented in Fig. 2. Mice receiving an intraarticular injection of commercial TCA (Kenalog-10) had higher withdrawal thresholds than PBS-injected mice over the day 1–11 post-injection period ($F=22.6$, $P=0.001$). On days, 3 and 5, these differences were also significant.

TCA-HA experiment

The von Frey force withdrawal thresholds are presented in Fig. 3. Mice receiving an intraarticular injection of TCA in 5% HA had higher withdrawal thresholds than PBS-injected mice or mice injected with 5% HA vehicle over the days 3–35 post-injection period ($F=17.8$, $P=0.0005$). On days 3, 7, 14, 21, and 28 these differences were also significant. The 5% HA alone did not increase force withdrawal thresholds compared to PBS.

Organ culture experiments

TCA exerts a potent anti-inflammatory effect on joints by inhibiting inflammatory cytokines and reduces OA associated pain¹², however, little is known about the mechanism of action of TCA in sensory neurons and reduction in OA associated pain. To delineate analgesic mechanisms of TCA, we performed organotypic slice cultures of spinal cord and DRG and assessed whether TCA can inhibit mediators of chronic pain induced by pro-inflammatory cytokine IL-1 β . In chronic pain stage, pro-inflammatory cytokine such as IL-1 β leads to release and/or activation of nociceptive molecules like NGF, CGRP, and inflammatory cytokines thereby altering sensitivity of sensory neurons.^{19–21} We, therefore incubated spinal cord slices and DRGs in the presence of IL-1 β (10ng/mL), TCA (1mg/mL) or combination of IL-1 β and TCA for 24 h, and the mRNA levels of pain mediators – NGF, CGRP, TNF α and CCL2 – were measured by qPCR. Concentration of IL-1 β was chosen based on the previous studies,^{19,22} while concentration of TCA was selected to closely match clinically relevant concentration. Our data show that TCA significantly suppressed IL-1 β -induced mRNA expression levels of NGF, CGRP, TNF α and CCL2 in DRG (Fig. 4) and NGF, TNF α and CCL2 in spinal cord slices (Fig. 5) organotypic culture.

DISCUSSION

HA is naturally found in knee joints: in the synovium, hyaline cartilage, and in the synovial fluid. Although HA solutions above 2% have high viscosity, they can be easily injected through fine-gauge needles (we used 30-gauge in the mouse study). Intraarticular injections of TCA are widely used to reduce OA knee pain in patients, yet the duration of action of the analgesic effect is often only weeks.^{3,6} Therefore combining TCA with a biocompatible matrix that could greatly prolong the duration of analgesic action is much needed.

The present IA injection experiments demonstrate that indeed 100 μ g TCA in a 5% HA matrix can produce a sustained anti-allodynia effect in mice with chronic surgically-induced OA. Interestingly, 5% HA alone had no therapeutic effect, which matches the meta-analysis

of patient studies in which in large, double-blinded sham-controlled trials there were no clinically important differences of HA treatment over placebo.¹³ One limitation of our study is that we did not perform a TCA dose-response for each of the formulations. The months involved in generating OA mice and the post steroid injection monitoring time (possibly over a month) somewhat restricted our animal numbers for the study.

Although use of TCA provides excellent results for OA-related chronic pain, however, the mechanism by which TCA exerts potent analgesic effect has not been fully elucidated. It is known that TCA exerts a potent anti-inflammatory effect on joints by inhibiting inflammatory cytokines and reduces chronic OA pain.¹² However, there are no studies to date that have examined the effect of TCA on sensory neurons. Our results from organotypic culture of spinal cord slices and DRG showed that TCA significantly attenuated mRNA expression levels of nociceptive molecules induced by IL-1 β in both spinal cord and DRG. During OA associated pain, mediators of pain such as NGF, CGRP, TNF α , CCL2 and IL-1 β have shown to be recruited into the OA joint and cause activation of peripheral nociceptors.^{9–11,23} The activation of these nociceptors is subsequently transmitted via the DRG, spinal cord and up through higher brain centers where signals are processed and perceived as pain. Thus, our current findings provide direct evidence of the mechanism by which TCA exerts analgesic effect.

Finally, these data in mice together with ex vivo provide rationale for evaluation of HA-based TCA formulations in man to mitigate and control pain for extended durations as compared to HA viscosupplementation and/or standard TCA injections alone. Such formulations may provide a welcome alternative for long-term control of chronic OA pain and may delay the need for knee replacement surgery.

Acknowledgments

This work was supported by NIH NIAMS grants R01 AR062136 (to HJ Im), R21 AR067935 (to HJ Im), a Veterans Affairs BLD&R Merit Review Award (to HJ Im), Arthritis Foundation (to HJ Im), F31 AR070002 (to JLH) and University Anesthesiologists, SC (to JSK).

Abbreviations

OA	osteoarthritis
TCA	triamcinolone acetate
TKR	knee replacement surgery
IA	intraarticular
DRG	dorsal root ganglion
NGF	nerve growth factor
CGRP	calcitonin gene-related peptide
TNFα	tumor necrosis factor- α
CCL2	chemokine (C-C motif) ligand 2

HA	hyaluronic acid
DMM	destabilization of the medial meniscus
HBSS	Hanks Balanced Salt Solution
IL-1β	interleukin 1 β
qPCR	quantitative PCR

References

- Altman RD, Hochberg M, Murphy WA Jr, Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society. 1995; 3(Suppl A):3–70.
- Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. The Journal of bone and joint surgery. American volume. 2007; 89:780–785. [PubMed: 17403800]
- Dieppe PA, Sathapatayavongs B, Jones HE, Bacon PA, Ring EF. Intra-articular steroids in osteoarthritis. Rheumatology and rehabilitation. 1980; 19:212–217. [PubMed: 7010511]
- Valtonen EJ. Clinical comparison of triamcinolonehexacetonide and betamethasone in the treatment of osteoarthritis of the knee-joint. Scandinavian journal of rheumatology. Supplement. 1981; 41:1–7. [PubMed: 6765509]
- Raynauld JP, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. 2003; 48:370–377. [PubMed: 12571845]
- Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. Bmj. 2004; 328:869. [PubMed: 15039276]
- Petrella RJ, et al. Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial. BMC musculoskeletal disorders. 2015; 16:57. [PubMed: 25887932]
- Bodick N, et al. An intra-articular, extended-release formulation of triamcinolone acetoneide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. The Journal of bone and joint surgery. American volume. 2015; 97:877–888. [PubMed: 26041848]
- Kc R, et al. PKCdelta null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth. Annals of the rheumatic diseases. 2016
- Dong T, et al. Calcitonin gene-related peptide can be selected as a predictive biomarker on progression and prognosis of knee osteoarthritis. International orthopaedics. 2015; 39:1237–1243. [PubMed: 25813459]
- Dawes JM, Kiesewetter H, Perkins JR, Bennett DL, McMahon SB. Chemokine expression in peripheral tissues from the monosodium iodoacetate model of chronic joint pain. Molecular pain. 2013; 9:57. [PubMed: 24206615]
- Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy. Nature reviews Rheumatology. 2014; 10:11–22. [PubMed: 24189839]
- Jevsevar D, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review of the Evidence. The Journal of bone and joint surgery. American volume. 2015; 97:2047–2060. [PubMed: 26677239]
- Knights CB, Gentry C, Bevan S. Partial medial meniscectomy produces osteoarthritis pain-related behaviour in female C57BL/6 mice. Pain. 2012; 153:281–292. [PubMed: 22001658]
- Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. Journal of neuroscience methods. 1994; 53:55–63. [PubMed: 7990513]

16. Courtney P, Doherty M. Joint aspiration and injection. Best practice & research Clinical rheumatology. 2005; 19:345–369. [PubMed: 15939363]
17. Aoki Y, et al. Axonal growth potential of lumbar dorsal root ganglion neurons in an organ culture system: response of nerve growth factor-sensitive neurons to neuronal injury and an inflammatory cytokine. Spine. 2007; 32:857–863. [PubMed: 17426629]
18. Marsh DR, Dekaban GA, Tan W, Strathdee CA, Weaver LC. Herpes simplex viral and amplicon vector-mediated gene transfer into glia and neurons in organotypic spinal cord and dorsal root ganglion cultures. Molecular therapy : the journal of the American Society of Gene Therapy. 2000; 1:464–478. [PubMed: 10933968]
19. Fehrenbacher JC, Burkey TH, Nicol GD, Vasko MR. Tumor necrosis factor alpha and interleukin-1beta stimulate the expression of cyclooxygenase II but do not alter prostaglandin E2 receptor mRNA levels in cultured dorsal root ganglia cells. Pain. 2005; 113:113–122. [PubMed: 15621371]
20. Oprea A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2000; 20:6289–6293. [PubMed: 10934280]
21. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain research reviews. 2009; 60:57–64. [PubMed: 19166877]
22. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2008; 28:5189–5194. [PubMed: 18480275]
23. Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. The Journal of rheumatology. 2008; 35:2306–2312. [PubMed: 18925684]

RESEARCH HIGHLIGHTS

- TCA reduces mechanical allodynia in mice with chronic surgically-induced OA
- TCA in a 5% HA matrix produces a prolonged anti-allodynia effect in mice with chronic surgically-induced OA
- TCA suppresses expression of pain mediators induced by IL-1 β in spinal cord slices and DRG organotypic culture

Figure 1. von Frey force withdrawal thresholds in mice with knee OA. Time 0 represents the chronic OA allodynic condition. Animals received a single IA injection of 40 μ g TCA in DMSO or PBS alone. N=8/group. *P* values are of the TCA-DMSO group vs. the PBS group.

Figure 2. von Frey force withdrawal thresholds in mice with knee OA. Time 0 represents the chronic OA allodynic condition. Animals received a single IA injection of a 40 μ g TCA suspension (Kenalog-10) or PBS alone. N=8/group. *P* values are of the TCA-Kenalog group vs. the PBS group.

Figure 3.

von Frey force withdrawal thresholds in mice with knee OA. Time 0 represents the chronic OA allodynic condition. Animals received a single IA injection of 100 μ g TCA in 5% HA, 5% HA alone, or PBS alone. N=8/group. *P* values are of the TCA-HA group vs. the other 2 groups.

Figure 4. qPCR analyses of NGF, CGRP, TNFα and CCL2 genes in organotypic DRG culture treated with IL-1β (10ng/mL), TCA (1mg/mL) or combination of IL-1β and TCA. The data are represented as mean ± SD. The level of statistical significance is indicated by asterisks ($P < 0.01$, **).

Figure 5. qPCR analyses of NGF, CGRP, TNFα and CCL2 genes in organotypic spinal cord slices culture treated with IL-1β (10ng/mL), TCA (1mg/mL) or combination of IL-1β and TCA. The data are represented as mean ± SD. The level of statistical significance is indicated by asterisks ($P < 0.05$, *; $P < 0.01$, **).